DOCSLIB.ORG

Neurotoxicology 73 (2019) 112–119

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Neurotoxicology 73 (2019) 112–119 Neurotoxicology 73 (2019) 112–119 Contents lists available at ScienceDirect Neurotoxicology journal homepage: www.elsevier.com/locate/neuro Full Length Article Activation of the immunoproteasome protects SH-SY5Y cells from the toxicity of rotenone T Congcong Suna, Mingshu Mob, Yun Wangc, Wenfei Yua, Chengyuan Songa, Xingbang Wanga, ⁎ Si Chena, Yiming Liua,d, a Department of Neurology, Qilu Hospital of Shandong University, Jinan, 250012, China b Department of Neurology, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, China c Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, 221000, China d Brain Science Research Institute, Shandong University, Jinan, 250012, China ARTICLE INFO ABSTRACT Keywords: This study investigated the expression and role of immunoproteasome (i-proteasome) in a cell model of Immunoproteasome Parkinson’s disease (PD). The cytotoxicity of rotenone was measured by CCK-8 assay. The i-proteasome β1i PSMB9 subunit PSMB9 was suppressed by a specific shRNA or transfected with an overexpression plasmid in the SH- ’ Parkinson s disease SY5Y cells. Under the exposure to rotenone or not, the expression of constitutive proteasome β subunits, i- Rotenone proteasome βi subunits, antigen presentation related proteins, α-syn and TH were detected by Western blot in PSMB9-silenced or -overexpressed cells, and the proteasomal activities were detected by fluorogenic peptide substrates. The location of i-proteasome βi subunits and α-syn were detected by immunofluorescence staining. The levels of ROS, GSH and MDA were measured by commercial kits. Cell apoptosis was detected by flow cytometry. Besides impairing the constitutive proteasomes, rotenone induced the expression of βi subunits of i- proteasome and antigen presentation related proteins such as TAP1, TAP2 and MHC-I. Silencing or over- expressing PSMB9 had no obvious effect on the levels of other subunits, but could regulate the chymotrypsin-like activity of 20S proteasome and the expression of TAP1, TAP2 and MHC-I. Three βi subunits (PSMB9, PSMB10, PSMB8) of i-proteasome were all co-localized with α-syn. PSMB9 knockdown aggravated accumulation of α-syn, degradation of TH, release of ROS, increased level of MDA, decreased level of GSH and eventually promoted apoptosis in SH-SY5Y cells after rotenone treatment, while over-expression of PSMB9 could attenuate these toxic effects of rotenone. I-proteasome is activated in SH-SY5Y cells treated with rotenone and may play a neuro- protective role. 1. Introduction particle and the 19S regulator particle. The catalytic 20S core particle contains three active subunits of β1, β2 and β5, which have caspase- Parkinson’s disease (PD) is the second most common neurodegen- like, trypsin-like and chymotrypsin-like peptidase activities, respec- erative disease in elderly people (Goedert and Compston, 2018). The tively (Eskandari et al., 2017). These subunits could be replaced by pathologic changes, which are characterized by loss of dopaminergic homologous subunits β1i (PSMB9), β2i (PSMB10) and β5i (PSMB8), neurons and deposition of abnormal α-synuclein (α-syn) in the sur- and the constitutive proteasome transforms into an immunoproteasome viving neurons, appear long before the onset of the classic movement (i-proteasome) under oxidative stress or inflammation conditions (Kaur disorders (Surmeier et al., 2017). Ubiquitin-proteasome pathway, and Batra, 2016). I-proteasome is a subtype of proteasome which could which plays a key role in maintaining protein homeostasis, is impaired degrade proteins and present optimal peptides to antigen presenting under these stresses, and subsequently induces the formation of harmful cells. Genetic polymorphisms in i-proteasome have been linked to protein aggregates (Mckinnon et al., 2015). neurodegenerative disease. For example, single nucleotide poly- Proteasomes consist of two main components: the catalytic 20S core morphisms located in PSMB9 could influence the proteasome activity in Abbreviations: i-proteasome, immunoproteasome; PD, Parkinson’s disease; α-syn, α-synuclein; AD, Alzheimer’s disease; SD, standard deviation ⁎ Corresponding author at: Department of Neurology, Qilu Hospital of Shandong University and Brain Science Research Institute, Shandong University, No.107, Wenhua West Road., Jinan, 250012, China. E-mail address: [email protected] (Y. Liu). https://doi.org/10.1016/j.neuro.2019.03.004 Received 11 September 2018; Received in revised form 13 March 2019; Accepted 18 March 2019 Available online 20 March 2019 0161-813X/ © 2019 Elsevier B.V. All rights reserved. C. Sun, et al. Neurotoxicology 73 (2019) 112–119 Alzheimer’s disease (AD) (Mishto et al., 2006). A previous study has Bioscience & Technology Co., Ltd, China), which contains the neomycin reported that rs17587 variants in PSMB9 gene might contribute to the selection marker. The vectors without the target gene and target of susceptibility of sporadic PD in Chinese females (Mo et al., 2016). βeta-actin were used as the negative control and positive control, re- Growing evidence shows that i-proteasome could be activated and spectively. Empty plasmids were used as the mock control. All plasmids might be involved in the pathogenesis of neurodegenerative disease were verified by DNA sequencing. The plasmids were transfected with with abnormal protein aggregation. For example, increased levels of Lipofectamine 2000 (Invitrogen, Grand Island, NY, USA) following the PSMB9 and PSMB8 have been detected in cortex and striatum of pa- manufacturer’s instructions. tients with Huntington’s disease (Díaz-Hernández et al., 2003). In- creased i-proteasome activity is found in human AD samples (Orre 2.4. Western blot et al., 2013). A trend of increased PSMB8 expression in remaining TH positive cells in Multiple system atrophy and Progressive supranuclear After treating with vehicles or 500 nM rotenone for 24 h, the whole- palsy has been reported (Bukhatwa et al., 2010). However, the ex- cell lysate was prepared by a Mammalian Cell Extraction Kit (Biovision, pression of i-proteasomes in PD is less studied and the results are CA, USA). The protein concentration was measured with a controversial as yet. Bukhatwa et al detected no obvious change of Bicinchoninic Acid (BCA) protein assay kit (Thermo Fisher Scientific PSMB8 expression in remaining TH positive cells in PD samples com- Inc., MA, USA). Soluble proteins (50 μg) were separated by 8–12% SDS- pared to control (Bukhatwa et al., 2010), while Ugras et al found in- polyacrylamide gels, and then transferred onto polyvinylidene di- creased levels and activity of PSMB8 in postmortem human brains with fluoride (PVDF) membranes (Millipore, MA, USA). Primary antibodies PD (Ugras et al., 2018). were as follows: rabbit anti-20 S proteasome β1(1: 1000, Abcam, Besides modulating inflammation, i-proteasome possess antioxidant Cambridge, MA, USA), mouse anti-20 S proteasome β2 (1: 1,000, capacity and proteolytic activity (Johnston-Carey et al., 2015; Kimura Abcam, Cambridge, MA, USA), rabbit anti-20 S proteasome β5 (1: et al., 2015). Augmented immunoproteasome function may contribute 1000, Abcam, Cambridge, MA, USA), rabbit anti-PSMB9 (1: 1,000, to lifespan diff ;erences in mice and among primate species (Pickering Abcam, Cambridge, MA, USA), rabbit anti-PSMB10 (1: 1,000, Abcam, et al., 2015). To investigate the role of i-proteasome in the pathophy- Cambridge, MA, USA), mouse anti-PSMB8 (1: 200, Santa Cruz siology of PD, we detected the exprssion and founction of βi subunits of Biotechnology, Inc., Santa Cruz, CA, USA), mouse anti-TAP1 (1: 2,00, i-proteasome in SH-SY5Y cells with rotenone toxicty, which is widely Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) and rabbit anti- used to imitate the pathogenesis of PD (Johnson and Bobrovskaya, TAP2 (1: 1,000, Abcam, Cambridge, MA, USA), rabbit anti-rat MHC-I 2015). (1:1000, Abcam, Cambridge, MA, USA), rabbit anti-TH (1: 1,000, Abcam, Cambridge, MA, USA), mouse anti-Alpha-synuclein (1: 1,000, 2. Materials and methods Abcam, Cambridge, MA, USA) and mouse anti- β-actin(1:10,000, Proteintech Group Inc., Chicago, IL, USA). Subsequently, membranes 2.1. Cell culture and rotenone treatment were washed and incubated with horseradish peroxidase (HRP)-con- jugated anti-mouse IgG or anti-rabbit IgG (KPL, MD, USA) secondary ® The SH-SY5Y cell line was obtained from American Type Culture antibodies. Proteins were detected by SuperSignal West Pico Collection (ATCC, Manassas, VA, USA), and was cultured in Dulbecco's Chemiluminescent Substrate (Thermo Fisher Scientific Inc., MA, USA). modified Eagle's high glucose medium (DMEM, Life Technologies, The densities were calculated as target protein expression/ β-actin ex- Rockville, MD, USA), supplemented with 10% fetal bovine serum (FBS, pression ratios with Image J 1.42q software (U.S. National Institutes of Invitrogen, CA, USA) in a humidified incubator with 5% CO2 at 37 °C. Health). Rotenone (Sigma-Aldrich, St Louis, MO, USA) was prepared in DMSO (Sigma-Aldrich, St Louis, MO, USA) and stocked at a con- 2.5. Proteasome activity measurement centration of 50 mM. Different concentrations of rotenone (0 nM, 10 nM, 100 nM, 500 nM, 1 u M, 10 u M) were diluted with DMEM re- Cells were treated with vehicles or 500 nM rotenone for 24 h. Then, spectively. Different incubation time (0 h, 3 h, 6 h, 12 h, 24 h, 48 h) was the proteasomal activity was measured with 20S proteasome activity carried out according to corresponding experiments and with vehicle as assay kit (Chemicon-Millipore, Billerica, MA, USA). Briefly, the cells control. were sonicated in cell lysis buffer (Thermo Scientific Pierce, Rockford, IL, USA). A BCA Protein Assay Kit (Thermo Fisher Scientifc, Rockford, 2.2. CCK-8 assay USA) was used to determine protein concentration. The isolated protein (50 μg) was incubated with buffer and 50 μM fluorogenic substrates (Z- Cells (5 × 103 cells/well) were seeded in a 96-well plate and in- LLE-AMC for caspase-like activity, Suc-LLVY-AMC for chymotrypsin- cubated overnight. Then cells were treated with vehicles or different like activity, and Z-ARR-AMC for trypsin-like activity) at 37 °C for 1 h.
Load more

Recommended publications
  • Genetic Variations in the PSMA6 and PSMC6 Proteasome Genes Are Associated with Multiple Sclerosis and Response to Interferon‑Β Therapy in Latvians
    EXPERIMENTAL AND THERAPEUTIC MEDICINE 21: 478, 2021 Genetic variations in the PSMA6 and PSMC6 proteasome genes are associated with multiple sclerosis and response to interferon‑β therapy in Latvians NATALIA PARAMONOVA1, JOLANTA KALNINA1, KRISTINE DOKANE1, KRISTINE DISLERE1, ILVA TRAPINA1, TATJANA SJAKSTE1 and NIKOLAJS SJAKSTE1,2 1Genomics and Bioinformatics, Institute of Biology of The University of Latvia; 2Department of Medical Biochemistry of The University of Latvia, LV‑1004 Riga, Latvia Received July 8, 2020; Accepted December 8, 2020 DOI: 10.3892/etm.2021.9909 Abstract. Several polymorphisms in genes related to the Introduction ubiquitin‑proteasome system exhibit an association with pathogenesis and prognosis of various human autoimmune Multiple sclerosis (MS) is a lifelong demyelinating disease of diseases. Our previous study reported the association the central nervous system. The clinical onset of MS tends to between multiple sclerosis (MS) and the PSMA3‑rs2348071 be between the second and fourth decade of life. Similarly to polymorphism in the Latvian population. The current study other autoimmune diseases, women are affected 3‑4 times more aimed to evaluate the PSMA6 and PSMC6 genetic variations, frequently than men (1). About 10% of MS patients experience their interaction between each other and with the rs2348071, a primary progressive MS form characterized by the progres‑ on the susceptibility to MS risk and response to therapy in sion of neurological disability from the onset. In about 90% the Latvian population. PSMA6‑rs2277460, ‑rs1048990 and of MS patients, the disease undergoes the relapse‑remitting PSMC6‑rs2295826, ‑rs2295827 were genotyped in the MS MS course (RRMS); in most of these patients, the condition case/control study and analysed in terms of genotype‑protein acquires secondary progressive course (SPMS) (2).
    [Show full text]
  • On the Role of the Immunoproteasome in Transplant Rejection
    Immunogenetics (2019) 71:263–271 https://doi.org/10.1007/s00251-018-1084-0 REVIEW On the role of the immunoproteasome in transplant rejection Michael Basler1,2 & Jun Li1,3 & Marcus Groettrup1,2 Received: 17 July 2018 /Accepted: 4 September 2018 /Published online: 15 September 2018 # Springer-Verlag GmbH Germany, part of Springer Nature 2018 Abstract The immunoproteasome is expressed in cells of hematopoietic origin and is induced during inflammation by IFN-γ. Targeting the immunoproteasome with selective inhibitors has been shown to be therapeutically effective in pre-clinical models for autoim- mune diseases, colitis-associated cancer formation, and transplantation. Immunoproteasome inhibition prevents activation and proliferation of lymphocytes, lowers MHC class I cell surface expression, reduces the expression of cytokines of activated immune cells, and curtails T helper 1 and 17 cell differentiation. This might explain the in vivo efficacy of immunoproteasome inhibition in different pre-clinical disease models for autoimmunity, cancer, and transplantation. In this review, we summarize the effect of immunoproteasome inhibition in different animal models for transplantation. Keywords Proteasome . Immunoproteasome . Antigen processing . Antigen presentation . Transplantation Introduction et al. 2012). Depending on the cell type and the presence or absence of the pro-inflammatory cytokine interferon (IFN)-γ, The proteasome is responsible for the degradation of proteins the three inducible β subunits of the immunoproteasome low in the cytoplasm and nuclei of all eukaryotic cells and exerts molecular mass polypeptide (LMP)2 (β1i), multicatalytic en- numerous essential regulatory functions in nearly all cell bio- dopeptidase complex-like (MECL)-1 (β2i), and LMP7 (β5i), logical pathways. The 26S proteasome degrades poly- can, in addition to the corresponding constitutive subunits ubiquitylated protein substrates and consists of a 19S regulator β1c, β2c, and β5c, enrich the cellular assortment of catalyti- and a 20S proteolytic core complex.
    [Show full text]
  • Molecular Pathology and Novel Clinical Therapy for Uterine
    ANTICANCER RESEARCH 36 : 4997-5008 (2016) doi:10.21873/anticanres.11068 Review Molecular Pathology and Novel Clinical Therapy for Uterine Leiomyosarcoma TAKUMA HAYASHI 1,2 , MIKI KAWANO 2,3 , TOMOYUKI ICHIMURA 4, KOICHI IDA 1, HIROFUMI ANDO 1, DORIT ZHARHARY 5, YAE KANAI 6, HIROYUKI ABURATANI 7, SUSUMU TONEGAWA 8, TANRI SHIOZAWA 1, NOBUO YAEGASHI 9 and IKUO KONISHI 10 1Department of Obstetrics and Gynecology, Shinshu University School of Medicine, Nagano, Japan; 2Department of Medical Technology, International University of Health and Welfare, Chiba, Japan; 3Department of Health Science, Kyushu University Graduate School of Medicine, Fukuoka, Japan; 4Department of Obstetrics and Gynecology, Osaka City University Graduate School of Medicine, Osaka, Japan; 5SIGMA-Aldrich Israel, Rehovot, Israel; 6Pathology Division, Keio University School of Medicine, Tokyo, Japan; 7The Cancer System Laboratory, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan; 8Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, U.S.A.; 9Department of Obstetrics and Gynecology, Tohoku University Graduate School of Medicine, Miyagi, Japan; 10 National Hospital Organization Kyoto Medical Centre, Kyoto, Japan Abstract. Patients with uterine leiomyosarcoma (LMS) disease prevalence of ~37% by 12 months of age. Furthermore, typically present with vaginal bleeding, pain, and a pelvic a recent report showed the loss of ability to induce PSMB9/ β1 i mass, with atypical presentations of hypercalcemia and expression,
    [Show full text]
  • Micrornas in the Etiology of Colorectal Cancer: Pathways and Clinical Implications Ashlee M
    Washington University School of Medicine Digital Commons@Becker Open Access Publications 2017 MicroRNAs in the etiology of colorectal cancer: Pathways and clinical implications Ashlee M. Strubberg Washington University School of Medicine in St. Louis Blair B. Madison Washington University School of Medicine in St. Louis Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs Recommended Citation Strubberg, Ashlee M. and Madison, Blair B., ,"MicroRNAs in the etiology of colorectal cancer: Pathways and clinical implications." Disease Models & Mechanisms.10,3. 197-214. (2017). https://digitalcommons.wustl.edu/open_access_pubs/5644 This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact [email protected]. © 2017. Published by The Company of Biologists Ltd | Disease Models & Mechanisms (2017) 10, 197-214 doi:10.1242/dmm.027441 REVIEW MicroRNAs in the etiology of colorectal cancer: pathways and clinical implications Ashlee M. Strubberg and Blair B. Madison* ABSTRACT rates from colorectal cancer have declined over the past 20 years, MicroRNAs (miRNAs) are small single-stranded RNAs that repress largely thanks to early detection; however, CRC incidence still mRNA translation and trigger mRNA degradation. Of the ∼1900 remains high (Siegel et al., 2015) and new treatments have been miRNA-encoding genes present in the human genome, ∼250 lagging. Treatment usually entails surgical removal of tumors, miRNAs are reported to have changes in abundance or altered which may be followed with chemotherapy and/or targeted functions in colorectal cancer.
    [Show full text]
  • Proteasome Immunosubunits Protect Against the Development of CD8 T Cell-Mediated Autoimmune Diseases
    Proteasome Immunosubunits Protect against the Development of CD8 T Cell-Mediated Autoimmune Diseases This information is current as Dietmar M. W. Zaiss, Cornelis P. J. Bekker, Andrea Gröne, of September 29, 2021. Benedicte A. Lie and Alice J. A. M. Sijts J Immunol published online 29 July 2011 http://www.jimmunol.org/content/early/2011/07/29/jimmun ol.1101003 Downloaded from Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision http://www.jimmunol.org/ • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: by guest on September 29, 2021 http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2011 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Published July 29, 2011, doi:10.4049/jimmunol.1101003 The Journal of Immunology Proteasome Immunosubunits Protect against the Development of CD8 T Cell-Mediated Autoimmune Diseases Dietmar M. W. Zaiss,* Cornelis P. J. Bekker,* Andrea Gro¨ne,† Benedicte A. Lie,‡ and Alice J. A. M. Sijts* Exposure of cells to inflammatory cytokines induces the expression of three proteasome immunosubunits, two of which are encoded in the MHC class II region.
    [Show full text]
  • Tyrosine Kinase Chromosomal Translocations Mediate Distinct and Overlapping Gene Regulation Events
    Kim et al. BMC Cancer 2011, 11:528 http://www.biomedcentral.com/1471-2407/11/528 RESEARCHARTICLE Open Access Tyrosine kinase chromosomal translocations mediate distinct and overlapping gene regulation events Hani Kim1,3, Lisa C Gillis1,2, Jordan D Jarvis1,2, Stuart Yang3, Kai Huang1, Sandy Der3 and Dwayne L Barber1,2,3* Abstract Background: Leukemia is a heterogeneous disease commonly associated with recurrent chromosomal translocations that involve tyrosine kinases including BCR-ABL, TEL-PDGFRB and TEL-JAK2. Most studies on the activated tyrosine kinases have focused on proximal signaling events, but little is known about gene transcription regulated by these fusions. Methods: Oligonucleotide microarray was performed to compare mRNA changes attributable to BCR-ABL, TEL- PDGFRB and TEL-JAK2 after 1 week of activation of each fusion in Ba/F3 cell lines. Imatinib was used to control the activation of BCR-ABL and TEL-PDGFRB, and TEL-JAK2-mediated gene expression was examined 1 week after Ba/F3- TEL-JAK2 cells were switched to factor-independent conditions. Results: Microarray analysis revealed between 800 to 2000 genes induced or suppressed by two-fold or greater by each tyrosine kinase, with a subset of these genes commonly induced or suppressed among the three fusions. Validation by Quantitative PCR confirmed that eight genes (Dok2, Mrvi1, Isg20, Id1, gp49b, Cxcl10, Scinderin, and collagen Va1(Col5a1)) displayed an overlapping regulation among the three tested fusion proteins. Stat1 and Gbp1 were induced uniquely by TEL-PDGFRB. Conclusions: Our results suggest that BCR-ABL, TEL-PDGFRB and TEL-JAK2 regulate distinct and overlapping gene transcription profiles.
    [Show full text]
  • The Role of the Immunoproteasome in Interferon-Γ-Mediated Microglial Activation Received: 4 May 2017 Kasey E
    www.nature.com/scientificreports OPEN The role of the immunoproteasome in interferon-γ-mediated microglial activation Received: 4 May 2017 Kasey E. Moritz1, Nikki M. McCormack1, Mahlet B. Abera2, Coralie Viollet3, Young J. Yauger1, Accepted: 14 July 2017 Gauthaman Sukumar3, Clifton L. Dalgard1,2,3,4 & Barrington G. Burnett 1,2 Published: xx xx xxxx Microglia regulate the brain microenvironment by sensing damage and neutralizing potentially harmful insults. Disruption of central nervous system (CNS) homeostasis results in transition of microglia to a reactive state characterized by morphological changes and production of cytokines to prevent further damage to CNS tissue. Immunoproteasome levels are elevated in activated microglia in models of stroke, infection and traumatic brain injury, though the exact role of the immunoproteasome in neuropathology remains poorly defned. Using gene expression analysis and native gel electrophoresis we characterize the expression and assembly of the immunoproteasome in microglia following interferon-gamma exposure. Transcriptome analysis suggests that the immunoproteasome regulates multiple features of microglial activation including nitric oxide production and phagocytosis. We show that inhibiting the immunoproteasome attenuates expression of pro-infammatory cytokines and suppresses interferon-gamma-dependent priming of microglia. These results imply that targeting immunoproteasome function following CNS injury may attenuate select microglial activity to improve the pathophysiology of neurodegenerative conditions or the progress of infammation-mediated secondary injury following neurotrauma. Microglia are the primary infammatory mediators of the central nervous system (CNS). Damage to the CNS results in the transition of microglia from a surveying or ‘ramifed’ state, to a ‘reactive’ state, allowing them to respond to changes in the local milieu1–3.
    [Show full text]
  • Intratumoral Injection of SYNB1891, a Synthetic Biotic Medicine Designed
    Intratumoral injection of SYNB1891 A Synthetic Biotic medicine designed to activate the innate immune system. Therapy demonstrates target engagement in humans including intratumoral STING activation. Janku F, MD Anderson Cancer Center; Luke JJ, UPMC Hillman Cancer Center; Brennan AM, Synlogic; Riese RJ, Synlogic; Varterasian M, Pharmaceutical Consultant; Kuhn K, Synlogic; Sokolovska A, Synlogic; Strauss J, Mary Crowley Cancer Research Presented by Filip Janku, MD, PhD Study supported by Synlogic, Inc American Association for Cancer Research (AACR) April 2021 Introduction and Methods SYNB1891 Strain Phase 1 First-in-Human Clinical Trial • Live, modified strain of the probiotic E. coli • Enrolling patients with refractory advanced solid Nissle engineered to produce cyclic tumors or lymphoma dinucleotides (CDN) under hypoxia leading to stimulator of interferon genes (STING)- • Intratumoral (IT) injection of SYNB1891 on Days activation 1, 8 and 15 of the first 21-day cycle and then on Day 1 of each subsequent cycle. • Preferentially taken up by phagocytic antigen- presenting cells in tumors, activating • Dose escalation planned across 7 cohorts (1x106 complementary innate immune pathways – 1x109 live cells) with Arm 1 consisting of (direct CDN STING activation; cGAS-mediated SYNB1891 as monotherapy, and Arm 2 in STING activation and TLR4/MyD88 activation by combination with atezolizumab the bacterial chassis) SYNB1891 was safe and well-tolerated in heterogenous population Nov 2020: Interim Analysis IA Updated through 15 Mar 2021 15 Mar 2021:
    [Show full text]
  • Biological Models of Colorectal Cancer Metastasis and Tumor Suppression
    BIOLOGICAL MODELS OF COLORECTAL CANCER METASTASIS AND TUMOR SUPPRESSION PROVIDE MECHANISTIC INSIGHTS TO GUIDE PERSONALIZED CARE OF THE COLORECTAL CANCER PATIENT By Jesse Joshua Smith Dissertation Submitted to the Faculty of the Graduate School of Vanderbilt University In partial fulfillment of the requirements For the degree of DOCTOR OF PHILOSOPHY In Cell and Developmental Biology May, 2010 Nashville, Tennessee Approved: Professor R. Daniel Beauchamp Professor Robert J. Coffey Professor Mark deCaestecker Professor Ethan Lee Professor Steven K. Hanks Copyright 2010 by Jesse Joshua Smith All Rights Reserved To my grandparents, Gladys and A.L. Lyth and Juanda Ruth and J.E. Smith, fully supportive and never in doubt. To my amazing and enduring parents, Rebecca Lyth and Jesse E. Smith, Jr., always there for me. .my sure foundation. To Jeannine, Bill and Reagan for encouragement, patience, love, trust and a solid backing. To Granny George and Shawn for loving support and care. And To my beautiful wife, Kelly, My heart, soul and great love, Infinitely supportive, patient and graceful. ii ACKNOWLEDGEMENTS This work would not have been possible without the financial support of the Vanderbilt Medical Scientist Training Program through the Clinical and Translational Science Award (Clinical Investigator Track), the Society of University Surgeons-Ethicon Scholarship Fund and the Surgical Oncology T32 grant and the Vanderbilt Medical Center Section of Surgical Sciences and the Department of Surgical Oncology. I am especially indebted to Drs. R. Daniel Beauchamp, Chairman of the Section of Surgical Sciences, Dr. James R. Goldenring, Vice Chairman of Research of the Department of Surgery, Dr. Naji N.
    [Show full text]
  • Additive Loss-Of-Function Proteasome Subunit Mutations in CANDLE/PRAAS Patients Promote Type I IFN Production
    Amendment history: Erratum (February 2016) Additive loss-of-function proteasome subunit mutations in CANDLE/PRAAS patients promote type I IFN production Anja Brehm, … , Ivona Aksentijevich, Raphaela Goldbach-Mansky J Clin Invest. 2015;125(11):4196-4211. https://doi.org/10.1172/JCI81260. Research Article Immunology Autosomal recessive mutations in proteasome subunit β 8 (PSMB8), which encodes the inducible proteasome subunit β5i, cause the immune-dysregulatory disease chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE), which is classified as a proteasome-associated autoinflammatory syndrome (PRAAS). Here, we identified 8 mutations in 4 proteasome genes, PSMA3 (encodes α7), PSMB4 (encodes β7), PSMB9 (encodes β1i), and proteasome maturation protein (POMP), that have not been previously associated with disease and 1 mutation inP SMB8 that has not been previously reported. One patient was compound heterozygous for PSMB4 mutations, 6 patients from 4 families were heterozygous for a missense mutation in 1 inducible proteasome subunit and a mutation in a constitutive proteasome subunit, and 1 patient was heterozygous for a POMP mutation, thus establishing a digenic and autosomal dominant inheritance pattern of PRAAS. Function evaluation revealed that these mutations variably affect transcription, protein expression, protein folding, proteasome assembly, and, ultimately, proteasome activity. Moreover, defects in proteasome formation and function were recapitulated by siRNA-mediated knockdown of the respective
    [Show full text]
  • PSMB9/LMP2 Rabbit Pab
    Leader in Biomolecular Solutions for Life Science PSMB9/LMP2 Rabbit pAb Catalog No.: A1771 1 Publications Basic Information Background Catalog No. The proteasome is a multicatalytic proteinase complex with a highly ordered ring- A1771 shaped 20S core structure. The core structure is composed of 4 rings of 28 non-identical subunits; 2 rings are composed of 7 alpha subunits and 2 rings are composed of 7 beta Observed MW subunits. Proteasomes are distributed throughout eukaryotic cells at a high 22kDa concentration and cleave peptides in an ATP/ubiquitin-dependent process in a non- lysosomal pathway. An essential function of a modified proteasome, the Calculated MW immunoproteasome, is the processing of class I MHC peptides. This gene encodes a 22kDa/23kDa member of the proteasome B-type family, also known as the T1B family, that is a 20S core beta subunit. This gene is located in the class II region of the MHC (major Category histocompatibility complex). Expression of this gene is induced by gamma interferon and this gene product replaces catalytic subunit 1 (proteasome beta 6 subunit) in the Primary antibody immunoproteasome. Proteolytic processing is required to generate a mature subunit. Applications WB, IF Cross-Reactivity Human, Mouse Recommended Dilutions Immunogen Information WB 1:500 - 1:2000 Gene ID Swiss Prot 5698 P28065 IF 1:10 - 1:100 Immunogen Recombinant fusion protein containing a sequence corresponding to amino acids 1-219 of human PSMB9/LMP2/LMP2 (NP_002791.1). Synonyms PSMB9;LMP2;PSMB6i;RING12;beta1i Contact Product Information www.abclonal.com Source Isotype Purification Rabbit IgG Affinity purification Storage Store at -20℃.
    [Show full text]
  • TNFR2 Signaling Regulates the Immunomodulatory Function of Oligodendrocyte Precursor Cells
    cells Article TNFR2 Signaling Regulates the Immunomodulatory Function of Oligodendrocyte Precursor Cells Haritha L. Desu 1, Placido Illiano 1, James S. Choi 1, Maureen C. Ascona 1, Han Gao 1,2, Jae K. Lee 1 and Roberta Brambilla 1,3,4,* 1 The Miami Project to Cure Paralysis, Department of Neurological Surgery, University of Miami Miller School of Medicine, Miami, FL 33136, USA; [email protected] (H.L.D.); [email protected] (P.I.); [email protected] (J.S.C.); [email protected] (M.C.A.); [email protected] (H.G.); [email protected] (J.K.L.) 2 Department of Spine Surgery, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510630, China 3 Department of Neurobiology Research, Institute of Molecular Medicine, and BRIDGE—Brain Research Inter Disciplinary Guided Excellence, 5000 Odense, Denmark 4 Department of Clinical Research, University of Southern Denmark, 5000 Odense, Denmark * Correspondence: [email protected]; Tel.: +305-243-3567 Abstract: Multiple sclerosis (MS) is a neuroimmune disorder characterized by inflammation, CNS demyelination, and progressive neurodegeneration. Chronic MS patients exhibit impaired remyeli- nation capacity, partly due to the changes that oligodendrocyte precursor cells (OPCs) undergo in response to the MS lesion environment. The cytokine tumor necrosis factor (TNF) is present in the MS-affected CNS and has been implicated in disease pathophysiology. Of the two active forms of TNF, transmembrane (tmTNF) and soluble (solTNF), tmTNF signals via TNFR2 mediating protective and reparative effects, including remyelination, whereas solTNF signals predominantly via TNFR1 Citation: Desu, H.L.; Illiano, P.; Choi, promoting neurotoxicity.
    [Show full text]